Scientific article
English

Cell encapsulation technology as a novel strategy for human anti-tumor immunotherapy

Published in

Cancer gene therapy, vol. 18, no. 8, p. 553-562

Publication date

2011

Abstract

Granulocyte-macrophage colony-stimulating factor (GM-CSF) as an adjuvant in autologous cell-based anti-tumor immunotherapy has recently been approved for clinical application. To avoid the need for individualized processing of autologous cells, we developed a novel strategy based on the encapsulation of GM-CSF-secreting human allogeneic cells. GM-CSF-producing K562 cells showed high, stable and reproducible cytokine secretion when enclosed into macrocapsules. For clinical development, the cryopreservation of these devices is critical. Thawing of capsules frozen at different time points displayed differences in GM-CSF release shortly after thawing. However, similar secretion values to those of non-frozen control capsules were obtained 8 days after thawing at a rate of >1000 ng GM-CSF per capsule every 24 h. For future human application, longer and reinforced capsules were designed. After irradiation and cryopreservation, these capsules produced >300 ng GM-CSF per capsule every 24 h 1 week after thawing. The in vivo implantation of encapsulated K562 cells was evaluated in mice and showed preserved cell survival. Finally, as a proof of principle of biological activity, capsules containing B16-GM-CSF allogeneic cells implanted in mice induced a prompt inflammatory reaction. The ability to reliably achieve high adjuvant release using a standardized procedure may lead to a new clinical application of GM-CSF in cell-based cancer immunization.

Keywords

  • Animals
  • Cell Line, Tumor
  • Female
  • Granulocyte-Macrophage Colony-Stimulating Factor/administration & dosage/chemistry/genetics/immunology
  • Humans
  • Immunotherapy/methods
  • K562 Cells
  • Mice
  • Mice, Inbred BALB C
  • Neoplasms/genetics/immunology/therapy

Citation (ISO format)

SCHWENTER, Frank et al. Cell encapsulation technology as a novel strategy for human anti-tumor immunotherapy. In: Cancer gene therapy, 2011, vol. 18, n° 8, p. 553–562. doi: 10.1038/cgt.2011.22

Main files (1)

Article (Published version)

Identifiers

Journal ISSN

0929-1903
917views
0downloads

Technical informations

Creation

29/11/2012 10:43:00

First validation

29/11/2012 10:43:00

Update

08/10/2024 16:16:18

Status update

08/10/2024 16:16:18

Last indexation

30/10/2024 08:12:08
All rights reserved by Archive ouverte UNIGE and the University of Geneva
OpenAIRE Indexed & Validated